Item 7.01. Regulation FD Disclosure
Pursuant to its existing share repurchase authority, on March 19, 2009, the
Company repurchased 4,511,657 shares of its common stock, par value $.01 per
share ("Common Stock"), from SB Holdings Capital Inc., a wholly-owned subsidiary
of GlaxoSmithKline plc., for an aggregate purchase price of $200,000,013.31. The
purchase price for the Common Stock reflected a negotiated discount to the
volume-weighted average trading price of the Common Stock in a trading period
preceding the purchase.
Add
DGX to Portfolio
Set Alert
Email to a
Friend